{
    "abstract": "The attenuated recombinant Vibrio cholerae O1 vaccine strain CVD 103-HgR, re-developed as PXVX0200, elicits a rapid serum vibriocidal antibody (SVA) response and protects against cholera diarrhea in volunteer challenge studies. We performed a phase 3, placebo controlled, double blind, multi-center study to further assess the safety, immunogenicity, and lot-to-lot consistency of PXVX0200. Adult volunteers 18\u201345 years of age were randomized 8:1 to receive a single dose of 1 \u00d7 109 CFU of PXVX0200 from three production lots or saline placebo. Immunogenicity endpoints included SVA and anti-cholera toxin (CT) antibody levels on days 1, 11, 29, 91 and 181. Safety was assessed by comparing solicited signs and symptoms on days 1\u20138, unsolicited adverse events through day 29 and serious adverse events through day 181. A total of 3146 participants were enrolled, including 2795 vaccine and 351 placebo recipients. The SVA seroconversion rates at day 11 were 94% and 4% in the PXVX0200 and placebo recipients, respectively (P <.0001). Cumulative SVA seroconversion occurred among 96% of vaccine recipients. PXVX0200 SVA GMTs peaked on day 11 and remained significantly higher than placebo through day 181 while the fold-rise over baseline in PXVX0200 anti-CT antibody was significantly greater than placebo at every post-vaccination time point. Most reactogenicity was mild and resolved within 1\u20133 days with headache and diarrhea more frequently reported in PXVX0200 recipients. There were no differences in unsolicited adverse events and no study-related serious adverse events. Immunogenicity and safety endpoints were equivalent between the three production lots. PXVX0200 is immunogenic and well tolerated across multiple production lots. Clinical Trials Registration: Clinicaltrials.gov NCT02094586.",
    "author_highlights": [
        {
            "endOffset": 11769,
            "sentence": "Phase 3 live, oral cholera vaccine CVD 103-HgR study in adults age 18\u201345.",
            "startOffset": 11696
        },
        {
            "endOffset": 11845,
            "sentence": "Measured safety, immunogenicity, lot consistency; most reactogenicity mild.",
            "startOffset": 11770
        },
        {
            "endOffset": 11927,
            "sentence": "Serum vibriocidal antibody seroconversion rate was 94% 10 days after vaccination.",
            "startOffset": 11846
        },
        {
            "endOffset": 12010,
            "sentence": "Vibriocidal antibodies persisted above baseline through 6 months post-vaccination.",
            "startOffset": 11928
        },
        {
            "endOffset": 12093,
            "sentence": "Immunogenicity and safety endpoints were equivalent between three production lots.",
            "startOffset": 12011
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Mohammad",
                    "initial": "M.",
                    "last": "Ali"
                },
                {
                    "first": "Anna Lena",
                    "initial": "A.L.",
                    "last": "Lopez"
                },
                {
                    "first": "Young Ae",
                    "initial": "Y.A.",
                    "last": "You"
                },
                {
                    "first": "Young Eun",
                    "initial": "Y.E.",
                    "last": "Kim"
                },
                {
                    "first": "Binod",
                    "initial": "B.",
                    "last": "Sah"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Maskery"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.2471/BLT.11.093427",
            "firstpage": "209",
            "issn": "00429686",
            "lastpage": "218",
            "pmid": "22461716",
            "pub_year": 2012,
            "title": "The global burden of cholera",
            "volume": "90"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Mohammad",
                    "initial": "M.",
                    "last": "Ali"
                },
                {
                    "first": "Allyson R.",
                    "initial": "A.R.",
                    "last": "Nelson"
                },
                {
                    "first": "Anna Lena",
                    "initial": "A.L.",
                    "last": "Lopez"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Sack"
                }
            ],
            "doi": "10.1371/journal.pntd.0003832",
            "issn": "19352727",
            "pmid": "26043000",
            "pub_year": 2015,
            "title": "Updated global burden of cholera in endemic countries",
            "volume": "9"
        },
        "b0020": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Loharikar"
                },
                {
                    "first": "A. E.",
                    "initial": "A.E.",
                    "last": "Newton"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Stroika"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Freeman"
                },
                {
                    "first": "K. D.",
                    "initial": "K.D.",
                    "last": "Greene"
                },
                {
                    "first": "M. B.",
                    "initial": "M.B.",
                    "last": "Parsons"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Bopp"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Talkington"
                },
                {
                    "first": "E. D.",
                    "initial": "E.D.",
                    "last": "Mintz"
                },
                {
                    "first": "B. E.",
                    "initial": "B.E.",
                    "last": "Mahon"
                }
            ],
            "doi": "10.1017/S0950268814001186",
            "firstpage": "695",
            "issn": "09502688",
            "lastpage": "703",
            "pmid": "24865664",
            "pub_year": 2015,
            "title": "Cholera in the United States, 2001-2011: A reflection of patterns of global epidemiology and travel",
            "volume": "143"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "De Schrijver"
                },
                {
                    "first": "Hilde",
                    "initial": "H.",
                    "last": "Boeckx"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Top"
                },
                {
                    "first": "An",
                    "initial": "A.",
                    "last": "Mertens"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "De Mol"
                }
            ],
            "doi": "10.1016/j.tmaid.2006.11.003",
            "firstpage": "236",
            "issn": "14778939",
            "lastpage": "238",
            "pmid": "17574145",
            "pub_year": 2007,
            "title": "Cholera among Belgian travellers in Turkey in 2005",
            "volume": "5"
        },
        "b0030": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Mascarello"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Deiana"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Maurel"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Lucarelli"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Luzzi"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Luzzati"
                }
            ],
            "doi": "10.2807/1560-7917.ES2013.18.35.20572",
            "issn": "1025496X",
            "pmid": "24008229",
            "pub_year": 2013,
            "title": "Cholera with severe renal failure in an Italian tourist returning from Cuba, July 2013",
            "volume": "18"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Steffen"
                },
                {
                    "first": "Jacques",
                    "initial": "J.",
                    "last": "Acar"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Walker"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Zuckerman"
                }
            ],
            "doi": "10.1016/S1477-8939(03)00062-0",
            "firstpage": "80",
            "issn": "14778939",
            "lastpage": "88",
            "pub_year": 2003,
            "title": "Cholera: Assessing the risk to travellers and identifying methods of protection",
            "volume": "1"
        },
        "b0040": {
            "authors": [
                {
                    "first": "G\u00fcnther",
                    "initial": "G.",
                    "last": "Slesak"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Fleck"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Jacob"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Grunow"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Sch\u00e4fer"
                }
            ],
            "doi": "10.2807/1560-7917.ES.2016.21.1.30099",
            "issn": "1025496X",
            "pmid": "26767388",
            "pub_year": 2016,
            "title": "Imported cholera with acute renal failure after a short business-trip to the Philippines, Germany, October 2015",
            "volume": "21"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Andr\u00e9s",
                    "initial": "A.",
                    "last": "Reyes-Corcho"
                },
                {
                    "first": "Richard W.",
                    "initial": "R.W.",
                    "last": "Pinsker"
                },
                {
                    "first": "Samir",
                    "initial": "S.",
                    "last": "Sarkar"
                },
                {
                    "first": "Farshad",
                    "initial": "F.",
                    "last": "Bagheri"
                },
                {
                    "first": "Mahendra C.",
                    "initial": "M.C.",
                    "last": "Patel"
                },
                {
                    "first": "Pablo",
                    "initial": "P.",
                    "last": "Lam"
                },
                {
                    "first": "Argentina",
                    "initial": "A.",
                    "last": "Gonz\u00e1lez"
                }
            ],
            "doi": "10.1016/j.tmaid.2012.10.002",
            "firstpage": "236",
            "issn": "14778939",
            "lastpage": "239",
            "pmid": "23137437",
            "pub_year": 2012,
            "title": "Cholera gravis associated with acute renal failure in a traveler from Haiti to the United States",
            "volume": "10"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Anna E.",
                    "initial": "A.E.",
                    "last": "Newton"
                },
                {
                    "first": "Katherine E.",
                    "initial": "K.E.",
                    "last": "Heiman"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Schmitz"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "T\u00f6r\u00f6k"
                },
                {
                    "first": "Andria",
                    "initial": "A.",
                    "last": "Apostolou"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Hanson"
                },
                {
                    "first": "Prabhu",
                    "initial": "P.",
                    "last": "Gounder"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Bohm"
                },
                {
                    "first": "Katie",
                    "initial": "K.",
                    "last": "Kurkjian"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Parsons"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Talkington"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Stroika"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Madoff"
                },
                {
                    "first": "Franny",
                    "initial": "F.",
                    "last": "Elson"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Sweat"
                },
                {
                    "first": "Venessa",
                    "initial": "V.",
                    "last": "Cantu"
                },
                {
                    "first": "Okey",
                    "initial": "O.",
                    "last": "Akwari"
                },
                {
                    "first": "Barbara E.",
                    "initial": "B.E.",
                    "last": "Mahon"
                },
                {
                    "first": "Eric D.",
                    "initial": "E.D.",
                    "last": "Mintz"
                }
            ],
            "doi": "10.3201/eid1711.110808",
            "firstpage": "2166",
            "issn": "10806040",
            "lastpage": "2168",
            "pub_year": 2011,
            "title": "Cholera in United States associated with epidemic in Hispaniola",
            "volume": "17"
        },
        "b0055": {
            "authors": [
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "D. R.",
                    "initial": "D.R.",
                    "last": "Nalin"
                },
                {
                    "first": "M. B.",
                    "initial": "M.B.",
                    "last": "Rennels"
                },
                {
                    "first": "R. B.",
                    "initial": "R.B.",
                    "last": "Hornick"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Sotman"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Van Blerk"
                },
                {
                    "first": "T. P.",
                    "initial": "T.P.",
                    "last": "Hughes"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "O'Donnell"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Barua"
                }
            ],
            "doi": "10.1080/03014467900003751",
            "firstpage": "369",
            "issn": "03014460",
            "lastpage": "374",
            "pmid": "394667",
            "pub_year": 1979,
            "title": "Genetic susceptibility to cholera",
            "volume": "6"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Ana A.",
                    "initial": "A.A.",
                    "last": "Weil"
                },
                {
                    "first": "Ashraful I.",
                    "initial": "A.I.",
                    "last": "Khan"
                },
                {
                    "first": "Fahima",
                    "initial": "F.",
                    "last": "Chowdhury"
                },
                {
                    "first": "Regina C.",
                    "initial": "R.C.",
                    "last": "LaRocque"
                },
                {
                    "first": "A. S.G.",
                    "initial": "A.S.G.",
                    "last": "Faruque"
                },
                {
                    "first": "Edward T.",
                    "initial": "E.T.",
                    "last": "Ryan"
                },
                {
                    "first": "Stephen B.",
                    "initial": "S.B.",
                    "last": "Calderwood"
                },
                {
                    "first": "Firdausi",
                    "initial": "F.",
                    "last": "Qadri"
                },
                {
                    "first": "Jason B.",
                    "initial": "J.B.",
                    "last": "Harris"
                }
            ],
            "doi": "10.1086/644779",
            "firstpage": "1473",
            "issn": "10584838",
            "lastpage": "1479",
            "pmid": "19842974",
            "pub_year": 2009,
            "title": "Clinical outcomes in household contacts of patients with cholera in Bangladesh",
            "volume": "49"
        },
        "b0065": {
            "authors": [
                {
                    "first": "W. H.",
                    "initial": "W.H.",
                    "last": "Mosley"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ahmad"
                },
                {
                    "first": "A. S.",
                    "initial": "A.S.",
                    "last": "Benenson"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahmed"
                }
            ],
            "firstpage": "777",
            "issn": "00429686",
            "lastpage": "785",
            "pmid": "5303331",
            "pub_year": 1968,
            "title": "The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients.",
            "volume": "38"
        },
        "b0070": {
            "authors": [
                {
                    "first": "R. M.",
                    "initial": "R.M.",
                    "last": "Robins-Browne"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Clements"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Young"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Black"
                },
                {
                    "first": "Y. L.",
                    "initial": "Y.L.",
                    "last": "Lim"
                },
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "Craig"
                }
            ],
            "doi": "10.1093/infdis/145.4.465",
            "firstpage": "465",
            "issn": "00221899",
            "lastpage": "473",
            "pmid": "7069227",
            "pub_year": 1982,
            "title": "Magnitude, kinetics, and duration of vibriocidal antibody responses in north americans after ingestion of vibrio cholerae",
            "volume": "145"
        },
        "b0075": {
            "authors": [
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Black"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Clements"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Cisneros"
                },
                {
                    "first": "D. R.",
                    "initial": "D.R.",
                    "last": "Nalin"
                },
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Young"
                }
            ],
            "doi": "10.1093/infdis/143.6.818",
            "firstpage": "818",
            "issn": "00221899",
            "lastpage": "820",
            "pmid": "7252264",
            "pub_year": 1981,
            "title": "Duration Of Infection-Derived Immunity To Cholera",
            "volume": "143"
        },
        "b0080": {
            "authors": [
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                }
            ],
            "doi": "10.1016/0020-2452(96)85758-7",
            "firstpage": "243",
            "issn": "00202452",
            "lastpage": "253",
            "pub_year": 1995,
            "title": "Live oral cholera vaccine : from principle to product",
            "volume": "93"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Deirdre",
                    "initial": "D.",
                    "last": "Herrington"
                },
                {
                    "first": "Genevieve",
                    "initial": "G.",
                    "last": "Losonsky"
                },
                {
                    "first": "Ben",
                    "initial": "B.",
                    "last": "Tall"
                },
                {
                    "first": "James B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "Julian",
                    "initial": "J.",
                    "last": "Ketley"
                },
                {
                    "first": "Carol O.",
                    "initial": "C.O.",
                    "last": "Tacket"
                },
                {
                    "first": "Stanley",
                    "initial": "S.",
                    "last": "Cryz"
                }
            ],
            "doi": "10.1016/S0140-6736(88)90120-1",
            "firstpage": "467",
            "issn": "01406736",
            "lastpage": "470",
            "pmid": "2900401",
            "pub_year": 1988,
            "title": "SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgR",
            "volume": "332"
        },
        "b0090": {
            "authors": [
                {
                    "first": "K. L.",
                    "initial": "K.L.",
                    "last": "Kotloff"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Wasserman"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "O'Donnell"
                },
                {
                    "first": "G. A.",
                    "initial": "G.A.",
                    "last": "Losonsky"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "firstpage": "4430",
            "issn": "00199567",
            "lastpage": "4432",
            "pmid": "1398956",
            "pub_year": 1992,
            "title": "Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind crossover trial",
            "volume": "60"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Carol O.",
                    "initial": "C.O.",
                    "last": "Tacket"
                },
                {
                    "first": "Mitchell B.",
                    "initial": "M.B.",
                    "last": "Cohen"
                },
                {
                    "first": "Steven S.",
                    "initial": "S.S.",
                    "last": "Wasserman"
                },
                {
                    "first": "Genevieve",
                    "initial": "G.",
                    "last": "Losonsky"
                },
                {
                    "first": "Sofie",
                    "initial": "S.",
                    "last": "Livio"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Kotloff"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Edelman"
                },
                {
                    "first": "James B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "Stanley J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "Ralph A.",
                    "initial": "R.A.",
                    "last": "Giannella"
                },
                {
                    "first": "Gilbert",
                    "initial": "G.",
                    "last": "Schiff"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "firstpage": "6341",
            "issn": "00199567",
            "lastpage": "6345",
            "pmid": "10569747",
            "pub_year": 1999,
            "title": "Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination",
            "volume": "67"
        },
        "b0100": {
            "authors": [
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "F\u00fcrer"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Althaus"
                }
            ],
            "doi": "10.1016/0264-410X(90)90012-B",
            "firstpage": "577",
            "issn": "0264410X",
            "lastpage": "580",
            "pmid": "2087879",
            "pub_year": 1990,
            "title": "Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults",
            "volume": "8"
        },
        "b0105": {
            "authors": [
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Losonsky"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Althaus"
                }
            ],
            "firstpage": "3916",
            "issn": "00199567",
            "lastpage": "3917",
            "pmid": "1500200",
            "pub_year": 1992,
            "title": "Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults",
            "volume": "60"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Wilbur H.",
                    "initial": "W.H.",
                    "last": "Chen"
                },
                {
                    "first": "James B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Lock"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Danzig"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Gurwith"
                }
            ],
            "doi": "10.1080/14760584.2017.1291348",
            "firstpage": "197",
            "issn": "14760584",
            "lastpage": "213",
            "pmid": "28165831",
            "pub_year": 2017,
            "title": "PaxVax CVD 103-HgR single-dose live oral cholera vaccine",
            "volume": "16"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Carol O.",
                    "initial": "C.O.",
                    "last": "Tacket"
                },
                {
                    "first": "Genevieve",
                    "initial": "G.",
                    "last": "Losonsky"
                },
                {
                    "first": "James P.",
                    "initial": "J.P.",
                    "last": "Nataro"
                },
                {
                    "first": "Stanley J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Edelman"
                },
                {
                    "first": "James B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1093/infdis/166.4.837",
            "firstpage": "837",
            "issn": "00221899",
            "lastpage": "841",
            "pmid": "1527420",
            "pub_year": 1992,
            "title": "Onset and Duration of Protective Immunity in Challenged Volunteers after Vaccination with Live Oral Cholera Vaccine CVD 103-HgR",
            "volume": "166"
        },
        "b0120": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Kollaritsch"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "A. B.",
                    "initial": "A.B.",
                    "last": "Lang"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Herzog"
                },
                {
                    "first": "J. U.",
                    "initial": "J.U.",
                    "last": "Que"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Wiedermann"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00101-8",
            "firstpage": "3031",
            "issn": "0264410X",
            "lastpage": "3039",
            "pmid": "10825607",
            "pub_year": 2000,
            "title": "Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization",
            "volume": "18"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Wilbur H.",
                    "initial": "W.H.",
                    "last": "Chen"
                },
                {
                    "first": "Richard N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "Marcela F.",
                    "initial": "M.F.",
                    "last": "Pasetti"
                },
                {
                    "first": "Sofie",
                    "initial": "S.",
                    "last": "Livio"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Lock"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Gurwith"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1128/CVI.00601-13",
            "firstpage": "66",
            "issn": "15566811",
            "lastpage": "73",
            "pmid": "24173028",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks",
            "volume": "21"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Wilbur H.",
                    "initial": "W.H.",
                    "last": "Chen"
                },
                {
                    "first": "Mitchell B.",
                    "initial": "M.B.",
                    "last": "Cohen"
                },
                {
                    "first": "Beth D.",
                    "initial": "B.D.",
                    "last": "Kirkpatrick"
                },
                {
                    "first": "Rebecca C.",
                    "initial": "R.C.",
                    "last": "Brady"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Galloway"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Gurwith"
                },
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Hall"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Kessler"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Lock"
                },
                {
                    "first": "Douglas",
                    "initial": "D.",
                    "last": "Haney"
                },
                {
                    "first": "Caroline E.",
                    "initial": "C.E.",
                    "last": "Lyon"
                },
                {
                    "first": "Marcela F.",
                    "initial": "M.F.",
                    "last": "Pasetti"
                },
                {
                    "first": "Jakub K.",
                    "initial": "J.K.",
                    "last": "Simon"
                },
                {
                    "first": "Flora",
                    "initial": "F.",
                    "last": "Szabo"
                },
                {
                    "first": "Sharon",
                    "initial": "S.",
                    "last": "Tennant"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1093/cid/ciw145",
            "firstpage": "1329",
            "issn": "10584838",
            "lastpage": "1335",
            "pmid": "27001804",
            "pub_year": 2016,
            "title": "Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor",
            "volume": "62"
        },
        "b0135": null,
        "b0140": {
            "authors": [
                {
                    "first": "A. S.",
                    "initial": "A.S.",
                    "last": "Benenson"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Saad"
                },
                {
                    "first": "W. H.",
                    "initial": "W.H.",
                    "last": "Mosley"
                }
            ],
            "firstpage": "277",
            "issn": "00429686",
            "lastpage": "285",
            "pmid": "5302303",
            "pub_year": 1968,
            "title": "Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.",
            "volume": "38"
        },
        "b0145": {
            "authors": [
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Young"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Black"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Takeda"
                },
                {
                    "first": "R. A.",
                    "initial": "R.A.",
                    "last": "Finkelstein"
                }
            ],
            "firstpage": "174",
            "issn": "00951137",
            "lastpage": "179",
            "pmid": "3882744",
            "pub_year": 1985,
            "title": "Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: Application in serodiagnosis and seroepidemiology",
            "volume": "21"
        },
        "b0150": {
            "authors": [
                {
                    "first": "D. L.",
                    "initial": "D.L.",
                    "last": "Swerdlow"
                },
                {
                    "first": "K. D.",
                    "initial": "K.D.",
                    "last": "Greene"
                },
                {
                    "first": "R. V.",
                    "initial": "R.V.",
                    "last": "Tauxe"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Wells"
                },
                {
                    "first": "N. H.",
                    "initial": "N.H.",
                    "last": "Bean"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Ries"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Blake"
                },
                {
                    "first": "E. D.",
                    "initial": "E.D.",
                    "last": "Mintz"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Pollack"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Rodriguez"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Tejada"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Seminario"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Ocampo"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Vertiz"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Espejo"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Saldana"
                }
            ],
            "doi": "10.1016/0140-6736(92)92432-F",
            "firstpage": "28",
            "issn": "01406736",
            "lastpage": "32",
            "pmid": "1351608",
            "pub_year": 1992,
            "title": "Waterborne transmission of epidemic cholera in Trujillo, Peru: lessons for a continent at risk",
            "volume": "340"
        },
        "b0155": {
            "authors": [],
            "firstpage": "1",
            "issn": "02561859",
            "lastpage": "4",
            "pmid": "1716942",
            "pub_year": 1991,
            "title": "Cholera situation in the Americas. An update.",
            "volume": "12"
        },
        "b0160": {
            "authors": [
                {
                    "first": "D. N.",
                    "initial": "D.N.",
                    "last": "Taylor"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Rizzo"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Meza"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Perez"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watts"
                }
            ],
            "doi": "10.1093/clinids/22.6.1108",
            "firstpage": "1108",
            "issn": "10584838",
            "lastpage": "1109",
            "pmid": "8783724",
            "pub_year": 1996,
            "title": "Cholera among Americans living in Peru",
            "volume": "22"
        },
        "b0165": null,
        "b0170": {
            "authors": [
                {
                    "first": "Ruxandra",
                    "initial": "R.",
                    "last": "Enzensberger"
                },
                {
                    "first": "Silke",
                    "initial": "S.",
                    "last": "Besier"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Baumg\u00e4rtner"
                },
                {
                    "first": "Volker",
                    "initial": "V.",
                    "last": "Brade"
                }
            ],
            "doi": "10.1080/00365540510026409",
            "firstpage": "73",
            "issn": "00365548",
            "lastpage": "75",
            "pmid": "15764195",
            "pub_year": 2005,
            "title": "Mixed diarrhoeal infection caused by Vibrio cholerae and several other enteric pathogens in a 4-year-old child returning to Germany from Pakistan",
            "volume": "37"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Raul",
                    "initial": "R.",
                    "last": "Neghina"
                },
                {
                    "first": "Adriana M.",
                    "initial": "A.M.",
                    "last": "Neghina"
                }
            ],
            "doi": "10.1097/IPC.0b013e318218334d",
            "firstpage": "148",
            "issn": "10569103",
            "lastpage": "149",
            "pub_year": 2012,
            "title": "A case of imported cholera in Romania in 2009",
            "volume": "20"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Sarah S.",
                    "initial": "S.S.",
                    "last": "Jackson"
                },
                {
                    "first": "Wilbur H.",
                    "initial": "W.H.",
                    "last": "Chen"
                }
            ],
            "doi": "10.2217/FMB.15.51",
            "firstpage": "1271",
            "issn": "17460913",
            "lastpage": "1281",
            "pmid": "26228388",
            "pub_year": 2015,
            "title": "Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine",
            "volume": "10"
        },
        "b0185": {
            "authors": [
                {
                    "first": "W. H.",
                    "initial": "W.H.",
                    "last": "Mosley"
                },
                {
                    "first": "A. S.",
                    "initial": "A.S.",
                    "last": "Benenson"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Barui"
                }
            ],
            "firstpage": "335",
            "issn": "00429686",
            "lastpage": "346",
            "pmid": "5302923",
            "pub_year": 1968,
            "title": "A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate.",
            "volume": "38"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Roger I.",
                    "initial": "R.I.",
                    "last": "Glass"
                },
                {
                    "first": "Ann Mari",
                    "initial": "A.M.",
                    "last": "Svennerholm"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Khan"
                },
                {
                    "first": "Shamsul",
                    "initial": "S.",
                    "last": "Huda"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Imdadul Huq"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Holmgren"
                }
            ],
            "doi": "10.1093/infdis/151.2.236",
            "firstpage": "236",
            "issn": "00221899",
            "lastpage": "242",
            "pmid": "3968450",
            "pub_year": 1985,
            "title": "Seroepidemiological studies of EI tor cholera in bangladesh: Association of serum antibody levels with protection",
            "volume": "151"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Richie"
                },
                {
                    "first": "Narain H.",
                    "initial": "N.H.",
                    "last": "Punjabi"
                },
                {
                    "first": "Yuwono",
                    "initial": "Y.",
                    "last": "Sidharta"
                },
                {
                    "first": "Kenny",
                    "initial": "K.",
                    "last": "Peetosutan"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Sukandar"
                },
                {
                    "first": "Steven S.",
                    "initial": "S.S.",
                    "last": "Wasserman"
                },
                {
                    "first": "Murad",
                    "initial": "M.",
                    "last": "Lesmana"
                },
                {
                    "first": "Ferry",
                    "initial": "F.",
                    "last": "Wangsasaputra"
                },
                {
                    "first": "Sri",
                    "initial": "S.",
                    "last": "Pandam"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "O'Hanley"
                },
                {
                    "first": "Stanley J.",
                    "initial": "S.J.",
                    "last": "Cryz"
                },
                {
                    "first": "Cyrus H.",
                    "initial": "C.H.",
                    "last": "Simanjuntak"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00006-2",
            "firstpage": "2399",
            "issn": "0264410X",
            "lastpage": "2410",
            "pmid": "10738097",
            "pub_year": 2000,
            "title": "Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area",
            "volume": "18"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Mohammad",
                    "initial": "M.",
                    "last": "Ali"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Emch"
                },
                {
                    "first": "Lorenz",
                    "initial": "L.",
                    "last": "Von Seidlein"
                },
                {
                    "first": "Mohammad",
                    "initial": "M.",
                    "last": "Yunus"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Sack"
                },
                {
                    "first": "Malla",
                    "initial": "M.",
                    "last": "Rao"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Holmgren"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1016/S0140-6736(05)66550-6",
            "firstpage": "44",
            "issn": "01406736",
            "lastpage": "49",
            "pmid": "15993232",
            "pub_year": 2005,
            "title": "Herd immunity conferred by killed oral cholera vaccines in Bangladesh: A reanalysis",
            "volume": "366"
        },
        "b0205": {
            "authors": [
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Herrington"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Losonsky"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Morris"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Clements"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Black"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Tall"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Hall"
                }
            ],
            "firstpage": "161",
            "issn": "00199567",
            "lastpage": "167",
            "pmid": "3335402",
            "pub_year": 1988,
            "title": "Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques",
            "volume": "56"
        },
        "b0210": {
            "authors": [
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Black"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Clements"
                }
            ],
            "firstpage": "510",
            "issn": "01460749",
            "lastpage": "550",
            "pmid": "6363898",
            "pub_year": 1983,
            "title": "New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development",
            "volume": "47"
        },
        "b0215": null,
        "b0220": {
            "authors": [
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Kaper"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Michalski"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Ketley"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "firstpage": "1480",
            "issn": "00199567",
            "lastpage": "1483",
            "pmid": "8132356",
            "pub_year": 1994,
            "title": "Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR",
            "volume": "62"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Jean Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Viret"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Dietrich"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Favre"
                }
            ],
            "doi": "10.1016/j.vaccine.2003.12.033",
            "firstpage": "2457",
            "issn": "0264410X",
            "lastpage": "2469",
            "pmid": "15193410",
            "pub_year": 2004,
            "title": "Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR",
            "volume": "22"
        }
    },
    "body_text": [
        {
            "endOffset": 25809,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Lot-to-lot geometric mean ratios [95% CI] at Day 11 were: Lot A/B 0.92 [0.78, 1.08]; Lot B/C 1.02 [0.87, 1.20]; and Lot A/C 0.94 [0.80, 1.10], all of which were within the pre-defined acceptance range of [0.67, 1.50].",
            "startOffset": 25592,
            "title": "Lot consistency"
        },
        {
            "endOffset": 18707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A subset of participants was selected via a convenience sample from some sites and voluntarily enrolled in an immune sub-study involving additional phlebotomy through 6 months post-vaccination.",
            "startOffset": 18514,
            "title": "Study design"
        },
        {
            "endOffset": 26844,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Of those reporting severe diarrhea, 19 subjects (82.6%) reported symptoms lasting 1 day, and 4 subjects (17.4%) reported symptoms lasting 2 days; no subjects reported symptoms lasting longer than two days.",
            "startOffset": 26639,
            "title": "Safety"
        },
        {
            "endOffset": 34262,
            "parents": [],
            "secId": "s0095",
            "sentence": "Diarrhea is the most important adverse effect with live cholera vaccine and was reported more frequently by vaccine recipients, with 3.9% reporting \u22654 stools in a 24-h period after vaccination versus 1.2% by placebo recipients.",
            "startOffset": 34035,
            "title": "Discussion"
        },
        {
            "endOffset": 31350,
            "parents": [],
            "secId": "s0095",
            "sentence": "Such findings have led to the use of cluster randomized study design, rather than individual randomization, for large field trials of cholera vaccines.",
            "startOffset": 31199,
            "title": "Discussion"
        },
        {
            "endOffset": 29356,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 29355,
                    "startOffset": 29339
                },
                "b0095": {
                    "endOffset": 29355,
                    "startOffset": 29339
                },
                "b0115": {
                    "endOffset": 29355,
                    "startOffset": 29339
                },
                "b0125": {
                    "endOffset": 29355,
                    "startOffset": 29339
                },
                "b0130": {
                    "endOffset": 29355,
                    "startOffset": 29339
                }
            },
            "secId": "s0095",
            "sentence": "This study further documents the safety and immunogenicity of single-dose, live oral cholera vaccine PXVX0200 and provides data consistent with previous studies [18,19,23,25,26].",
            "startOffset": 29178,
            "title": "Discussion"
        },
        {
            "endOffset": 35201,
            "parents": [],
            "secId": "s0100",
            "sentence": "PXVX0200 is safe and produces a robust consistent vibriocidal antibody response across multiple production lots that should provide protection against cholera in adults from developed countries who are at increased risk of infection when traveling or residing in at-risk countries.",
            "startOffset": 34920,
            "title": "Conclusion"
        },
        {
            "endOffset": 16138,
            "parents": [],
            "secId": "s0005",
            "sentence": "In 2009, PaxVax acquired a worldwide, exclusive license to the strain CVD 103-HgR with the aim of redeveloping the cholera vaccine.",
            "startOffset": 16007,
            "title": "Background"
        },
        {
            "endOffset": 20074,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Sera from the immune sub-study participants were tested for SVA and anti-cholera toxin (anti-CT) antibody at additional visits through 6 months post-vaccination.",
            "startOffset": 19913,
            "title": "Immunology"
        },
        {
            "endOffset": 16480,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 16479,
                    "startOffset": 16475
                }
            },
            "secId": "s0005",
            "sentence": "A double-blind, randomized, placebo-controlled phase 1 study in adults 18\u201350 years of age demonstrated PXVX0200 was well tolerated with vibriocidal and anti-cholera toxin seroconversion rates of 89% and 57%, respectively [25].",
            "startOffset": 16254,
            "title": "Background"
        },
        {
            "endOffset": 22688,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Ninety-five percent CIs were calculated for each frequency using the Clopper-Pearson method, and frequencies were compared using Fisher\u2019s exact tests.",
            "startOffset": 22538,
            "title": "Safety"
        },
        {
            "endOffset": 20746,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0035",
            "sentence": "The GMTs of vaccine and placebo recipients were compared using a t-test on log-transformed titers; seroconversion rates were compared using a Fisher\u2019s exact test.",
            "startOffset": 20584,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34909,
            "parents": [],
            "secId": "s0095",
            "sentence": "There were no differences in reactogenicity or adverse events between the three production lots, again documenting consistency in the manufacturing process.",
            "startOffset": 34753,
            "title": "Discussion"
        },
        {
            "endOffset": 20583,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0035",
            "sentence": "SVA titers were summarized by geometric mean titers (GMTs) and 95% CIs at baseline (Day 1) and Day 11 (\u22123 to +5 days), and by the seroconversion rate defined as the percentage of subjects who had a 4-fold or greater increase in SVA titer.",
            "startOffset": 20345,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 23668,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Reasons for exclusion included incorrect randomization, sample availability, and missed visits at Day 11.",
            "startOffset": 23563,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32253,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 32219,
                    "startOffset": 32215
                }
            },
            "secId": "s0095",
            "sentence": "While vibriocidal GMTs were unaffected by blood type, race and ethnicity, they were significantly lower in older individuals within the age range tested, although vibriocidal seroconversion, which has been shown to be strongly correlated with protection [26], was not significantly different.",
            "startOffset": 31961,
            "title": "Discussion"
        },
        {
            "endOffset": 18029,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Eligibility criteria included healthy men and women aged 18\u201345 without significant medical history or physical exam findings during screening, without history of cholera or enterotoxigenic E. coli infection, and with no travel to a cholera-endemic region in the previous 5 years.",
            "startOffset": 17750,
            "title": "Study design"
        },
        {
            "endOffset": 25209,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Vibriocidal antibody GMTs (95% CI) of PXVX0200 recipients peaked at a geometric mean of 9922 (4306\u201322,865) on Day 11 and decreased through Day 181, at which point titers remained significantly greater than placebo (Fig. 2).",
            "startOffset": 24986,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 27262,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Over half (57.2% [95% CI: 54.7\u201359.7%]) of women reported at least one sign or symptom compared to 45.4% (42.5\u201348.2%) of men.",
            "startOffset": 27138,
            "title": "Safety"
        },
        {
            "endOffset": 30635,
            "parents": [],
            "secId": "s0095",
            "sentence": "However, during the course of the follow-up, there was a marked reduction in the cholera incidence in the study population overall.",
            "startOffset": 30504,
            "title": "Discussion"
        },
        {
            "endOffset": 28994,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 28993,
                    "startOffset": 28980
                },
                "b0030": {
                    "endOffset": 28993,
                    "startOffset": 28980
                },
                "b0040": {
                    "endOffset": 28993,
                    "startOffset": 28980
                },
                "b0160": {
                    "endOffset": 28993,
                    "startOffset": 28980
                },
                "b0165": {
                    "endOffset": 28993,
                    "startOffset": 28980
                },
                "b0170": {
                    "endOffset": 28993,
                    "startOffset": 28980
                },
                "b0175": {
                    "endOffset": 28993,
                    "startOffset": 28980
                }
            },
            "secId": "s0095",
            "sentence": "Individuals from industrialized countries who travel to developing countries where cholera is present are at risk of cholera which can be severe and even fatal [5,6,8,32\u201335].",
            "startOffset": 28820,
            "title": "Discussion"
        },
        {
            "endOffset": 34589,
            "parents": [],
            "secId": "s0095",
            "sentence": "She was found to also be infected with enteropathogenic E. coli and this organism may have contributed to the severity of her illness.",
            "startOffset": 34455,
            "title": "Discussion"
        },
        {
            "endOffset": 27137,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "PXVX0200 recipient safety analysis summarized by sex showed a trend in women reporting reactogenicity more frequently than men for all signs and symptoms except fever.",
            "startOffset": 26970,
            "title": "Safety"
        },
        {
            "endOffset": 27870,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Unsolicited AEs recorded through Day 29 showed 23.0% of PXVX0200 recipients and 24.0% of placebo recipients reporting one AE.",
            "startOffset": 27745,
            "title": "Adverse events"
        },
        {
            "endOffset": 31660,
            "parents": [],
            "secId": "s0095",
            "sentence": "In the current study, three different lots of PXVX0200 were shown to have immunologic equivalence based on the serum vibriocidal GMTs 10 days (Day 11) post-vaccination as well as seroconversion rates of 94%, 93% and 94% for Lots A, B and C, respectively, demonstrating consistency of the manufacturing process.",
            "startOffset": 31350,
            "title": "Discussion"
        },
        {
            "endOffset": 14695,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 14694,
                    "startOffset": 14687
                },
                "b0060": {
                    "endOffset": 14694,
                    "startOffset": 14687
                }
            },
            "secId": "s0005",
            "sentence": "Those with blood group O and certain medical conditions, such as hypochlorhydria and chronic renal and heart disease, are at increased risk for severe disease (cholera gravis) [11,12].",
            "startOffset": 14511,
            "title": "Background"
        },
        {
            "endOffset": 28036,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Most AEs were mild for both groups and an examination of AEs identified no trends showing a higher proportion of either PXVX0200 or placebo recipients reporting AEs.",
            "startOffset": 27871,
            "title": "Adverse events"
        },
        {
            "endOffset": 17611,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This study was a multi-center phase 3 randomized, double-blind, placebo-controlled trial, performed at 19 US and 6 Australian sites, designed to assess PXVX0200 immunogenicity, safety, and manufacturing consistency.",
            "startOffset": 17396,
            "title": "Study design"
        },
        {
            "endOffset": 14960,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 14959,
                    "startOffset": 14952
                },
                "b0070": {
                    "endOffset": 14959,
                    "startOffset": 14952
                }
            },
            "secId": "s0005",
            "sentence": "Infection with either naturally or experimentally acquired cholera induces serum vibriocidal antibodies (SVA) and these antibodies are associated with a reduced risk of cholera infection, with a stronger vibriocidal response resulting in greater protection [13,14].",
            "startOffset": 14695,
            "title": "Background"
        },
        {
            "endOffset": 31025,
            "parents": [],
            "secId": "s0095",
            "sentence": "Rather than attribute this observation to a lack of efficacy, an alternative explanation is that indirect protection (i.e., herd immunity) may have contributed to the reduction of cholera among controls as well as vaccinees, thus making it more difficult to detect a vaccine effect.",
            "startOffset": 30743,
            "title": "Discussion"
        },
        {
            "endOffset": 19912,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Serum samples were tested 10 days after vaccination (Day 11) for classical Inaba vibriocidal antibody titer to determine immunogenicity.",
            "startOffset": 19776,
            "title": "Immunology"
        },
        {
            "endOffset": 26010,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Most reactogenicity reported was mild and resolved within 1\u20133 days.",
            "startOffset": 25943,
            "title": "Safety"
        },
        {
            "endOffset": 16254,
            "parents": [],
            "secId": "s0005",
            "sentence": "The PaxVax research name for the vaccine, prepared from new CVD 103-HgR master and working cell banks, is PXVX0200.",
            "startOffset": 16139,
            "title": "Background"
        },
        {
            "endOffset": 28684,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Diarrhea decreased to 5 stools on Day 4 and to 3 stools on Day 5 and resolved by Day 6.",
            "startOffset": 28597,
            "title": "Adverse events"
        },
        {
            "endOffset": 33155,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 33154,
                    "startOffset": 33150
                }
            },
            "secId": "s0095",
            "sentence": "These results are similar to those seen in the recent experimental V. cholerae challenge study where the immune response persisted for at least six months and vibriocidal antibody seroconversion strongly correlated with protection against moderate-to-severe cholera [26].",
            "startOffset": 32884,
            "title": "Discussion"
        },
        {
            "endOffset": 28819,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 28818,
                    "startOffset": 28811
                },
                "b0155": {
                    "endOffset": 28818,
                    "startOffset": 28811
                }
            },
            "secId": "s0095",
            "sentence": "Cholera is a potentially lethal infection which occurs worldwide in both an endemic form and in explosive outbreaks [30,31].",
            "startOffset": 28695,
            "title": "Discussion"
        },
        {
            "endOffset": 34034,
            "parents": [],
            "secId": "s0095",
            "sentence": "Most vaccine reactogenicity was mild and resolved within three days; tiredness and headache were most common.",
            "startOffset": 33925,
            "title": "Discussion"
        },
        {
            "endOffset": 30503,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 30502,
                    "startOffset": 30498
                }
            },
            "secId": "s0095",
            "sentence": "A large-double blind, individual-randomized, placebo controlled study (33,696 vaccinees and 33,812 controls) conducted in Indonesia failed to show significant protection over 4 years of follow-up [39].",
            "startOffset": 30302,
            "title": "Discussion"
        },
        {
            "endOffset": 17749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Study protocols were reviewed by institutional review boards (IRB) at each study site and informed consent was obtained before screening.",
            "startOffset": 17612,
            "title": "Study design"
        },
        {
            "endOffset": 25591,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Seroconversion rates among the three individual lots were equivalent.",
            "startOffset": 25522,
            "title": "Lot consistency"
        },
        {
            "endOffset": 29567,
            "parents": [],
            "secId": "s0095",
            "sentence": "Seroconversion, defined as a \u22654-fold rise in vibriocidal antibody against homologous classical Inaba, occurred in 94% of vaccine recipients versus 4% in placebo recipients (p < .0001) 10 days after vaccination.",
            "startOffset": 29357,
            "title": "Discussion"
        },
        {
            "endOffset": 21480,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "SVA GMTs were analyzed at each time point using the same methods as the main study.",
            "startOffset": 21397,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 24048,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In a general linear model, both sex (p < .0001) and age (p = .0213) had a significant impact on SVA at Day 11.",
            "startOffset": 23938,
            "title": "Effect of baseline characteristics on immunogenicity"
        },
        {
            "endOffset": 31198,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 31197,
                    "startOffset": 31193
                }
            },
            "secId": "s0095",
            "sentence": "In a reanalysis of field study data from Bangladesh, Ali et al. noted that as vaccine coverage increased, cholera incidence fell in both the placebo and vaccine group [40].",
            "startOffset": 31026,
            "title": "Discussion"
        },
        {
            "endOffset": 22022,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Fisher\u2019s tests were used to compare the cumulative vibriocidal seroconversion rates of vaccine and placebo recipients at each time point.",
            "startOffset": 21885,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 27624,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Summary by blood type revealed no differences in frequency of reporting reactogenicity.",
            "startOffset": 27537,
            "title": "Safety"
        },
        {
            "endOffset": 14260,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14259,
                    "startOffset": 14254
                },
                "b0015": {
                    "endOffset": 14259,
                    "startOffset": 14254
                }
            },
            "secId": "s0005",
            "sentence": "Cholera is endemic in 69 countries, with epidemiology studies suggesting as many as 4 million cases and 143,000 deaths annually in endemic countries and 2500 deaths annually in non-endemic countries [2,3].",
            "startOffset": 14055,
            "title": "Background"
        },
        {
            "endOffset": 18898,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Solicited reactogenicity signs and symptoms included daily temperature, presence of tiredness, headache, lack of appetite, nausea and vomiting, diarrhea, and abdominal pain on study days 1\u20138.",
            "startOffset": 18707,
            "title": "Study design"
        },
        {
            "endOffset": 23009,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Unsolicited treatment-emergent AEs were summarized by System Organ Class (SOC) and Preferred Term (PT), by count and percent for PXVX0200 and placebo groups.",
            "startOffset": 22852,
            "title": "Safety"
        },
        {
            "endOffset": 21884,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "SVA was also summarized by the cumulative seroconversion rate at each post-baseline time point, defined as the percentage of subjects with a \u22654-fold increase over baseline titer prior to or at that time point.",
            "startOffset": 21675,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 22280,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Ninety-five percent CIs for each ratio were constructed on log-transformed data and then back-transformed to the original scale.",
            "startOffset": 22152,
            "title": "Lot equivalence"
        },
        {
            "endOffset": 22151,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The serum vibriocidal GMTs of Lots A, B, and C at Day 11 were combined to form three ratios: A/B, A/C, and B/C.",
            "startOffset": 22040,
            "title": "Lot equivalence"
        },
        {
            "endOffset": 22386,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Predefined criteria for equivalence required the 95% CI on each pairwise ratio to be within [0.67, 1.50].",
            "startOffset": 22281,
            "title": "Lot equivalence"
        },
        {
            "endOffset": 15839,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0090": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0095": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0100": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0105": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0110": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0115": {
                    "endOffset": 15838,
                    "startOffset": 15831
                },
                "b0120": {
                    "endOffset": 15838,
                    "startOffset": 15831
                }
            },
            "secId": "s0005",
            "sentence": "It was shown to be safe in multiple clinical studies and efficacy was demonstrated in cholera challenge studies in healthy volunteers, with protection against wild type V. cholerae O1 of Inaba or Ogawa serotypes and classical or El Tor biotypes noted from eight days to six months after vaccination and evidence of persistent antibody response at 3.5 years [17\u201324].",
            "startOffset": 15474,
            "title": "Background"
        },
        {
            "endOffset": 26499,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The frequency of diarrhea of moderate or worse severity (\u22655 stools per 24 h after vaccination), reported by 1.5% (1.1\u20132.0%) and 0.3% (0\u20131.6%) of PXVX0200 and placebo recipients, respectively, approached statistical significance (p = .0809).",
            "startOffset": 26259,
            "title": "Safety"
        },
        {
            "endOffset": 26638,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Severe diarrhea (\u22656 stools per 24 h) was reported by 23 of 2789 (0.8%) of PXVX0200 recipients and 0 of 350 placebo recipients (p = .1014).",
            "startOffset": 26500,
            "title": "Safety"
        },
        {
            "endOffset": 30302,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 30301,
                    "startOffset": 30294
                },
                "b0115": {
                    "endOffset": 30301,
                    "startOffset": 30294
                }
            },
            "secId": "s0095",
            "sentence": "Previous studies with CVD 103-HgR demonstrated protection against experimental challenge with both classical and El Tor biotypes of V. cholerae and also protection against experimental challenge six months after vaccination [17,23].",
            "startOffset": 30070,
            "title": "Discussion"
        },
        {
            "endOffset": 24985,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Cumulative SVA seroconversion occurred among 96% of PXVX0200 recipients followed through Day 181, and all SVA seroconversion occurred by Day 29.",
            "startOffset": 24841,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 24455,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Vibriocidal antibody titer declined with age: the GMT (95% CI) was about twice as high for 18\u201324 year-olds (12,519 [11,128\u201314,082]) compared to 39\u201345 year-olds (6692 [5706\u20137849]).",
            "startOffset": 24276,
            "title": "Effect of baseline characteristics on immunogenicity"
        },
        {
            "endOffset": 25317,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Anti-CT GMTs (95% CI) of PXVX0200 recipients peaked at 2007 (1075\u20133748) on Day 29, and decreased thereafter.",
            "startOffset": 25209,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 23562,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The seroconversion rate (95% CI) at Day 11 was 94% (93\u201394%) for the PXVX0200 group and 4% (2\u20137%) for the placebo group (p < .0001) (Table 2).",
            "startOffset": 23421,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24751,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Neither age nor sex had a significant impact on the Day 11 seroconversion rate when assessed in a logistic regression model that incorporated the same factors as the titer analysis; the differences in titer due to age and sex were not large enough to have a significant impact on seroconversion.",
            "startOffset": 24456,
            "title": "Effect of baseline characteristics on immunogenicity"
        },
        {
            "endOffset": 33284,
            "parents": [],
            "secId": "s0095",
            "sentence": "Anti-CT GMT peaked on Day 29 and the fold-rise in anti-CT antibody remained significantly above placebo at all follow up visits.",
            "startOffset": 33156,
            "title": "Discussion"
        },
        {
            "endOffset": 25942,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The frequency and severity of reactogenicity signs and symptoms for PXVX0200 and placebo recipients are reported in Table 3.",
            "startOffset": 25818,
            "title": "Safety"
        },
        {
            "endOffset": 18513,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Eligible study participants were randomized 8:1 to receive either a single oral dose of PXVX0200 or a physiological saline placebo.",
            "startOffset": 18382,
            "title": "Study design"
        },
        {
            "endOffset": 23139,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In total, 3146 participants were randomized (Fig. 1) and participant demographics are described in Table 1.",
            "startOffset": 23032,
            "title": "Demographics"
        },
        {
            "endOffset": 30742,
            "parents": [],
            "secId": "s0095",
            "sentence": "Originally intended for 3 years, the study was extended a fourth year in an attempt to capture more cases.",
            "startOffset": 30636,
            "title": "Discussion"
        },
        {
            "endOffset": 20303,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 20302,
                    "startOffset": 20295
                },
                "b0145": {
                    "endOffset": 20302,
                    "startOffset": 20295
                }
            },
            "secId": "s0025",
            "sentence": "These assays were performed at Focus Diagnostics, Inc. using assays with previously described methods transferred from the Applied Immunology Unit at the Center for Vaccine Development, University of Baltimore, Maryland [28,29].",
            "startOffset": 20075,
            "title": "Immunology"
        },
        {
            "endOffset": 26258,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Diarrhea of any severity, defined as \u22654 stools per 24 h after vaccination, was reported by 3.9% (3.2\u20134.7%) of PXVX0200 recipients and by 1.2% (0.3\u20132.9%) of placebo recipients (p = .0079).",
            "startOffset": 26071,
            "title": "Safety"
        },
        {
            "endOffset": 23883,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The cause of the other 10 placebo seroconverters could be due to error but is unknown.",
            "startOffset": 23797,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31960,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 31798,
                    "startOffset": 31791
                },
                "b0130": {
                    "endOffset": 31798,
                    "startOffset": 31791
                }
            },
            "secId": "s0095",
            "sentence": "Notably, the peak vibriocidal GMTs in this study were numerically higher than the peaks seen in the phase 1 and challenge studies [25,26], possibly because this study used a dose at the higher end of the release criteria (1 x 109 CFU/dose) than those used in the earlier trials (4\u20135 \u00d7 108 CFU/dose).",
            "startOffset": 31661,
            "title": "Discussion"
        },
        {
            "endOffset": 33561,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 33560,
                    "startOffset": 33550
                },
                "b0205": {
                    "endOffset": 33560,
                    "startOffset": 33550
                },
                "b0210": {
                    "endOffset": 33560,
                    "startOffset": 33550
                }
            },
            "secId": "s0095",
            "sentence": "While anti-CT antibodies may add to the protection conferred by cholera vaccine, vibriocidal antibody is considered the more important factor in protection against cholera, and SVA seroconversion was the best predictor of protection in the PXVX0200 challenge study [26,41,42].",
            "startOffset": 33285,
            "title": "Discussion"
        },
        {
            "endOffset": 34752,
            "parents": [],
            "refoffsets": {
                "b0220": {
                    "endOffset": 34751,
                    "startOffset": 34744
                },
                "b0225": {
                    "endOffset": 34751,
                    "startOffset": 34744
                }
            },
            "secId": "s0095",
            "sentence": "Although the V. cholerae isolate was not saved and not available for further study, it is extremely unlikely for PXVX0200 to revert to a toxigenic strain [44,45].",
            "startOffset": 34590,
            "title": "Discussion"
        },
        {
            "endOffset": 22537,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Solicited reactogenicity was summarized by the frequency of each solicited reactogenicity sign and symptom in the PXVX0200 and placebo groups.",
            "startOffset": 22395,
            "title": "Safety"
        },
        {
            "endOffset": 20988,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0035",
            "sentence": "The effect of baseline characteristics on SVA was explored in a general linear model with log Day 11 vibriocidal antibody titer as the response variable and blood group, age, sex, race, ethnicity and log baseline vibriocidal titer as factors.",
            "startOffset": 20746,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 19104,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Unsolicited reactogenicity signs and symptoms were recorded as adverse events (AEs), and were monitored through Day 29, with an additional phone call follow-up for serious adverse events (SAEs) at Day 181.",
            "startOffset": 18899,
            "title": "Study design"
        },
        {
            "endOffset": 15357,
            "parents": [],
            "secId": "s0005",
            "sentence": "This duration of infection-derived immunity suggested that a promising approach to development of cholera vaccines may be to mimic natural immunity with orally administered, attenuated strains of V. cholerae.",
            "startOffset": 15149,
            "title": "Background"
        },
        {
            "endOffset": 23796,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "We identified that 4 subjects assigned to the placebo group mistakenly received vaccine but were analyzed in the placebo group.",
            "startOffset": 23669,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 19580,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "At reconstitution, the single-dose PXVX0200 solution contained 1 \u00d7 109 CFU.",
            "startOffset": 19505,
            "title": "Vaccine"
        },
        {
            "endOffset": 23420,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The immunogenicity evaluable population was 2688 (96.2%), based upon the availability of Day 11 immunogenicity data.",
            "startOffset": 23304,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 14510,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 14509,
                    "startOffset": 14503
                },
                "b0050": {
                    "endOffset": 14509,
                    "startOffset": 14503
                }
            },
            "secId": "s0005",
            "sentence": "Travelers at risk include individuals traveling to visit friends and relatives, relief workers, and tourists [4,10].",
            "startOffset": 14394,
            "title": "Background"
        },
        {
            "endOffset": 29178,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 29177,
                    "startOffset": 29170
                },
                "b0180": {
                    "endOffset": 29177,
                    "startOffset": 29170
                }
            },
            "secId": "s0095",
            "sentence": "For travelers at risk, including those in high risk groups and those leaving on short notice, a single-dose cholera vaccine that provides rapid protection is considered ideal [16,36].",
            "startOffset": 28995,
            "title": "Discussion"
        },
        {
            "endOffset": 24275,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The difference between males and females was modest with GMTs (95% CI) about 10% higher for males (10,252 [9291\u201311,312]) than females (9251, [8459\u201310,118]).",
            "startOffset": 24119,
            "title": "Effect of baseline characteristics on immunogenicity"
        },
        {
            "endOffset": 21122,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0035",
            "sentence": "A logistic regression model with the same factors was used to assess the effect of baseline characteristics on Day 11 seroconversion.",
            "startOffset": 20989,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32883,
            "parents": [],
            "secId": "s0095",
            "sentence": "Vibriocidal GMT peaked on Day 11 and gradually declined over the six-month study but remained significantly above vibriocidal GMT values of placebo recipients at each visit.",
            "startOffset": 32710,
            "title": "Discussion"
        },
        {
            "endOffset": 32525,
            "parents": [],
            "secId": "s0095",
            "sentence": "The immune sub-study characterized the kinetics of vibriocidal and anti-CT antibodies over time.",
            "startOffset": 32429,
            "title": "Discussion"
        },
        {
            "endOffset": 15148,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 15147,
                    "startOffset": 15143
                }
            },
            "secId": "s0005",
            "sentence": "Challenge with V. cholerae mimics natural infection and induces protective immunity against re-challenge with homologous and heterologous strains that lasts for at least three years [15].",
            "startOffset": 14961,
            "title": "Background"
        },
        {
            "endOffset": 27536,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Summary by race showed 54.4% (52.1\u201356.6%) of white participants reported at least one sign or symptom of reactogenicity compared to 43.2% (39.5\u201347.1%) of African-American or black participants, a trend which held for all signs or symptoms except fever and lack of appetite.",
            "startOffset": 27263,
            "title": "Safety"
        },
        {
            "endOffset": 19504,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Lyophilized PXVX0200 sachets stored at \u221220 \u00b0C were reconstituted in a sodium bicarbonate buffer, made using 100 mL of bottled water and single-dose buffer sachets containing 2.5 g NaHCO3, 1.5 g ascorbic acid, and 0.2 g lactose.",
            "startOffset": 19277,
            "title": "Vaccine"
        },
        {
            "endOffset": 22851,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Frequencies and CIs were also calculated by sex (male and female), race (white, and African American or black), and blood type (O and non-O blood type) subgroups.",
            "startOffset": 22689,
            "title": "Safety"
        },
        {
            "endOffset": 19763,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Three production lots manufactured by PaxVax, Inc (San Diego, CA, USA) under cGMP, Lot A (P700.550-1CA03), Lot B (P700.550-3CA03), and Lot C (P700.550-6BA03), were used in the study.",
            "startOffset": 19581,
            "title": "Vaccine"
        },
        {
            "endOffset": 34405,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 34404,
                    "startOffset": 34394
                },
                "b0125": {
                    "endOffset": 34404,
                    "startOffset": 34394
                },
                "b0215": {
                    "endOffset": 34404,
                    "startOffset": 34394
                }
            },
            "secId": "s0095",
            "sentence": "This is similar to the rates of diarrhea seen with previous studies of PXVX0200 and with the previously commercialized formulation [19,25,43].",
            "startOffset": 34263,
            "title": "Discussion"
        },
        {
            "endOffset": 14393,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 14392,
                    "startOffset": 14387
                },
                "b0025": {
                    "endOffset": 14392,
                    "startOffset": 14387
                },
                "b0030": {
                    "endOffset": 14392,
                    "startOffset": 14387
                },
                "b0035": {
                    "endOffset": 14392,
                    "startOffset": 14387
                },
                "b0040": {
                    "endOffset": 14392,
                    "startOffset": 14387
                },
                "b0045": {
                    "endOffset": 14392,
                    "startOffset": 14387
                }
            },
            "secId": "s0005",
            "sentence": "It also presents an ongoing risk for travelers to countries with cholera epidemics, as well as countries with endemic cholera [4\u20139].",
            "startOffset": 14261,
            "title": "Background"
        },
        {
            "endOffset": 17128,
            "parents": [],
            "secId": "s0005",
            "sentence": "This phase 3 study was designed to further characterize the safety and immunogenicity of PXVX0200 and to demonstrate the consistency of the manufacturing process by documenting the immunologic equivalence of different production lots.",
            "startOffset": 16894,
            "title": "Background"
        },
        {
            "endOffset": 16738,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 16737,
                    "startOffset": 16733
                }
            },
            "secId": "s0005",
            "sentence": "A phase 3 study in adults who received PXVX0200 or placebo and were subsequently challenged with 1 \u00d7 105 CFU of wild-type V. cholerae O1 El Tor Inaba strain N16961 demonstrated protective efficacy of 90% at 10 days and 80% at 3 months post vaccination [26].",
            "startOffset": 16481,
            "title": "Background"
        },
        {
            "endOffset": 18073,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Travel was not restricted during the study.",
            "startOffset": 18030,
            "title": "Study design"
        },
        {
            "endOffset": 28514,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The vaccinee had no evidence of hemodynamic instability, received 1 L of intravenous fluids and was sent home.",
            "startOffset": 28404,
            "title": "Adverse events"
        },
        {
            "endOffset": 15473,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 15472,
                    "startOffset": 15468
                }
            },
            "secId": "s0005",
            "sentence": "CVD 103-HgR is a live, attenuated recombinant V. cholerae O1 strain that does not produce active cholera toxin [16].",
            "startOffset": 15357,
            "title": "Background"
        },
        {
            "endOffset": 26071,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "There were no differences between the three production lots.",
            "startOffset": 26011,
            "title": "Safety"
        },
        {
            "endOffset": 21674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Anti-CT antibody was summarized at each time by the geometric mean of the fold-rise in antibody over baseline; treatment groups were compared using t-tests on log-transformed fold-rise results.",
            "startOffset": 21481,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 26970,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Differences for all other reactogenicity signs and symptoms of at least moderate severity were not statistically significant.",
            "startOffset": 26845,
            "title": "Safety"
        },
        {
            "endOffset": 14054,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 14053,
                    "startOffset": 14050
                }
            },
            "secId": "s0005",
            "sentence": "Vibrio cholerae causes potentially life-threatening diarrhea and remains a major public health problem in much of the developing world [1].",
            "startOffset": 13915,
            "title": "Background"
        },
        {
            "endOffset": 33924,
            "parents": [],
            "refoffsets": {
                "b0215": {
                    "endOffset": 33923,
                    "startOffset": 33919
                }
            },
            "secId": "s0095",
            "sentence": "Our study, which comprises a large portion of the PXVX0200 safety database, demonstrated the vaccine was well tolerated, with a safety profile similar to that previously observed with Orochol [43].",
            "startOffset": 33727,
            "title": "Discussion"
        },
        {
            "endOffset": 16006,
            "parents": [],
            "secId": "s0005",
            "sentence": "It was approved in a number of countries under the names Orochol and Orochol E, but was never approved in the US, and was discontinued in 2001 for commercial reasons.",
            "startOffset": 15840,
            "title": "Background"
        },
        {
            "endOffset": 23287,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The immune sub-study population included 26 PXVX0200 and six placebo recipients, with comparable demographics to the overall randomized population.",
            "startOffset": 23140,
            "title": "Demographics"
        },
        {
            "endOffset": 28596,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Stool cultures tested positive for both V. cholerae and enteropathogenic E. coli.",
            "startOffset": 28515,
            "title": "Adverse events"
        },
        {
            "endOffset": 17373,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 17372,
                    "startOffset": 17368
                }
            },
            "secId": "s0005",
            "sentence": "The sample size of this study generated a large portion of the PXVX0200 safety database, supporting its approval for use in the US in 2016 under the trade name Vaxchora\u00ae, the only cholera vaccine available for US travelers since the 1980s [27].",
            "startOffset": 17129,
            "title": "Background"
        },
        {
            "endOffset": 32429,
            "parents": [],
            "secId": "s0095",
            "sentence": "The association between age and vibriocidal antibody response has recently been evaluated in a phase 3 study of PXVX0200 in older adults age 46\u201364 (manuscript in preparation).",
            "startOffset": 32254,
            "title": "Discussion"
        },
        {
            "endOffset": 24118,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The effects of blood group, race, and ethnicity were not significant.",
            "startOffset": 24049,
            "title": "Effect of baseline characteristics on immunogenicity"
        },
        {
            "endOffset": 34454,
            "parents": [],
            "secId": "s0095",
            "sentence": "One vaccine recipient developed severe diarrhea.",
            "startOffset": 34406,
            "title": "Discussion"
        },
        {
            "endOffset": 30069,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 30068,
                    "startOffset": 30064
                }
            },
            "secId": "s0095",
            "sentence": "In particular, the phase 3 challenge trial of PXVX0200 demonstrated a strong correlation between vaccine-induced SVA seroconversion and protection against moderate to severe cholera in a prospective, controlled setting [26].",
            "startOffset": 29845,
            "title": "Discussion"
        },
        {
            "endOffset": 24840,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Immune sub-study antibody analyses are shown in Figs. 2 and 3.",
            "startOffset": 24778,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 16894,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 16893,
                    "startOffset": 16889
                }
            },
            "secId": "s0005",
            "sentence": "Evidence of cross-strain protection was documented with consistent vibriocidal antibody responses noted across all V. cholerae biotypes and serotypes [22].",
            "startOffset": 16739,
            "title": "Background"
        },
        {
            "endOffset": 18381,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Exclusion criteria included abnormal stool patterns, defined as fewer than 3 stools per week or greater than 2 stools per day in the past 6 months, regular use of laxatives in the past 6 months, and the use of antibiotics or chloroquine within 14 days prior to vaccination through 11 days after vaccination.",
            "startOffset": 18074,
            "title": "Study design"
        },
        {
            "endOffset": 19267,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For serum antibody assays, blood was collected from all participants on Days 1 and 11, and additionally from immune sub-study participants on Days 29, 91, and 181.",
            "startOffset": 19104,
            "title": "Study design"
        },
        {
            "endOffset": 28403,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "One severe non-serious AE was considered related to the study product: a vaccine recipient developed severe diarrhea (18 bowel movements in 24 h) on Day 3 which required treatment in an emergency room.",
            "startOffset": 28202,
            "title": "Adverse events"
        },
        {
            "endOffset": 33727,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 33726,
                    "startOffset": 33722
                }
            },
            "secId": "s0095",
            "sentence": "The vibriocidal immune response to PXVX0200 is consistent across O1 cholera strains, including classical Inaba, El Tor Inaba, classical Ogawa, and El Tor Ogawa [22].",
            "startOffset": 33562,
            "title": "Discussion"
        },
        {
            "endOffset": 25504,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The fold-rise over baseline in anti-CT antibody was significantly greater in PXVX0200 recipients than in placebo recipients at every post-vaccination time point through Day 181 (Fig. 3).",
            "startOffset": 25318,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 27728,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The incidence and severity of reactogenicity reported were consistent among all three productions lots.",
            "startOffset": 27625,
            "title": "Safety"
        },
        {
            "endOffset": 29844,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0090": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0095": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0115": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0125": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0130": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0185": {
                    "endOffset": 29843,
                    "startOffset": 29821
                },
                "b0190": {
                    "endOffset": 29843,
                    "startOffset": 29821
                }
            },
            "secId": "s0095",
            "sentence": "These results are similar to the vibriocidal antibody seroconversion rates of >90% seen in prior studies and, since vibriocidal antibody has long been known to be a correlate of protection, would be predicted to protect against cholera-induced diarrhea [17\u201319,23,25,26,37,38].",
            "startOffset": 29568,
            "title": "Discussion"
        },
        {
            "endOffset": 21396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "To characterize immune response kinetics over time, SVA and anti-CT antibody were assessed through 6 months-post-vaccination at Days 1, 11 (\u22123 to +5 days), 29, 91 and 181 (\u00b17 days, each) in the 32 subjects who participated in the immune sub-study.",
            "startOffset": 21149,
            "title": "Immune response kinetics"
        },
        {
            "endOffset": 28202,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "There were 19 SAEs in 17 PXVX0200 recipients (0.6%) and 4 SAEs in 3 placebo recipients (0.9%); none were considered related to the study and all resolved by Day 181.",
            "startOffset": 28037,
            "title": "Adverse events"
        },
        {
            "endOffset": 32709,
            "parents": [],
            "secId": "s0095",
            "sentence": "Cumulative vibriocidal seroconversion, defined as a vibriocidal antibody titer at least 4-fold higher than pre-vaccination, occurred in 96% of vaccine recipients and peaked on Day 29.",
            "startOffset": 32526,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X17318236",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "James M.",
                "initial": "J.M.",
                "last": "McCarty"
            },
            {
                "email": null,
                "first": "Michael D.",
                "initial": "M.D.",
                "last": "Lock"
            },
            {
                "email": null,
                "first": "Kristin M.",
                "initial": "K.M.",
                "last": "Hunt"
            },
            {
                "email": null,
                "first": "Jakub K.",
                "initial": "J.K.",
                "last": "Simon"
            },
            {
                "email": "mgurwith@paxvax.com",
                "first": "Marc",
                "initial": "M.",
                "last": "Gurwith"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.12.062",
        "firstpage": "833",
        "issn": "0264410X",
        "lastpage": "840",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18\u201345"
    }
}